GeneDx Holdings Corp. (WGS) came out with quarterly earnings of $0.5 per share, beating the Zacks Consensus Estimate of $0.1 per share. This compares to a loss of $0.11 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +400.00%. A quarter ago, it was expected that this company would post earnings of $0.11 per share when it actually produced earnings of $0.28, delivering a surprise of +154.55%.Over the last four quarters, the com ...

GeneDx (Nasdaq: WGS) 2Q 2025 Earnings Presentation July 29, 2025 On average: 16 tests and 5 years before an accurate diagnosis Forward Looking Statements This presentation contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our future performance, future operations, plans, objectives of management, and our market opportunity, including our expected full year 2025 reported revenue, volume, adjusted gross margin and adjusted net income. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 Commission file number 001-39482 GeneDx Holdings Corp. 333 Ludlow Street, North Tower; 6th Floor Stamford, Connecticut 06902 (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code: (888) 729-1206 Securities registered pursuant to Section 12(b) of ...

Exhibit 99.1 GeneDx Reports Second Quarter 2025 Financial Results and Business Highlights GAITHERSBURG, Md., July 29, 2025 — GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the second quarter of 2025. "Crossing the $100 million revenue mark and delivering our fourth consecutive profitable quarter is a major milestone for GeneDx, putting us on a path for more growth at scale and enabling us to reach more p ...

Core Insights - GeneDx Holdings Corp. has consistently surpassed earnings estimates, averaging a 202.27% beat over the last two quarters [1][2] - The company reported earnings of $0.28 per share against a consensus estimate of $0.11, resulting in a surprise of 154.55% for the last quarter [2] - For the previous quarter, earnings were $0.7 per share compared to an expected $0.2, delivering a surprise of 250.00% [2] Earnings Estimates and Predictions - Estimates for GeneDx Holdings have been trending higher due to its history of earnings surprises [5] - The stock has a positive Zacks Earnings ESP of +5.26%, indicating bullish sentiment among analysts regarding future earnings [8] - The combination of a positive Earnings ESP and a Zacks Rank of 2 (Buy) suggests a strong likelihood of another earnings beat in the upcoming report [8] Earnings ESP and Market Behavior - Stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have a nearly 70% chance of producing a positive surprise [6] - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, reflecting the latest analyst revisions [7] - A negative Earnings ESP can reduce predictive power but does not necessarily indicate an earnings miss [9]

Core Insights - GeneDx Holdings Corp. is set to report its second-quarter 2025 results on July 29, with strong expectations based on previous performance and estimates [1][10] Financial Performance - The company reported first-quarter adjusted earnings of 28 cents per share, exceeding the Zacks Consensus Estimate by 154.55%, marking a consistent trend of earnings beats over the past four quarters with an average surprise of 145.82% [1] - The Zacks Consensus Estimate for second-quarter revenues is $84.7 million, indicating a 20.1% increase from the previous year, while the EPS estimate is 10 cents, reflecting a significant year-over-year increase of 190.9% [2] Estimate Revisions - Earnings estimates have increased by 11.1% to 10 cents in the last 30 days, indicating positive sentiment ahead of the earnings announcement [3] Growth Drivers - Revenue growth is anticipated to be driven by Exome and genome tests, with a notable 24% year-over-year increase in test volume during the first quarter, contributing to a 62% revenue increase [4] - The acquisition of Fabric Genomics is expected to enhance GeneDx's capabilities in AI-powered genomic interpretation, facilitating a more comprehensive approach to genomic medicine [5] - The launch of ultraRapid Whole Genome Sequencing is projected to provide faster diagnoses for neonatal and pediatric patients, further contributing to revenue growth [7] Operational Efficiency - The company achieved a 56% growth in adjusted gross profit from continuing operations in the first quarter, leading to a 69% increase in gross margin, with expectations of continued operational efficiency in the second quarter [8] Market Position - GeneDx's strong performance in pediatric neurology and new testing indications is likely to drive outpatient volume growth, positioning the company favorably in the market [9]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of GeneDx Holdings Corp due to allegations of materially misleading business information [1] Group 1: Legal Actions and Investigations - Shareholders who purchased GeneDx securities may be entitled to compensation through a class action without any out-of-pocket fees [2] - A report by Grizzly Research accused GeneDx of committing widespread fraud, claiming that its growth is an illusion driven by fraudulent schemes [3] Group 2: Stock Performance - Following the allegations from Grizzly Research, GeneDx's stock price fell by $4.84, or 6.7%, closing at $67.18 per share on February 5, 2025 [3] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4] - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4]

Company Overview - GeneDx Holdings is a healthcare technology company that integrates AI and machine learning with clinical and genomic data, focusing on precision medicine and individualized patient care [7] - The company has a market capitalization of $2.29 billion and reported a revenue of $330 million with a net income of -$38.6 million for the trailing twelve months [6] Recent Financial Performance - GeneDx Holdings shares have appreciated by 141.5% over the past year as of July 11, 2025 [5] - The company reported a 42% year-over-year increase in revenue for the first quarter, driven by high volumes of exome and genome tests [9] - Revenue from exome and genome tests accounted for 82% of GeneDx's total Q1 revenue, with the net loss for the quarter shrinking to $6.5 million from $20 million in the prior-year period [10] Insider Activity - On July 11, 2025, Kevin Feeley, CFO of GeneDx Holdings, sold 5,278 shares, reducing his holdings to 3,392 shares, which represents approximately 0.01% of total shares outstanding [1][4] - This sale is consistent with Feeley's recent trading patterns, as it is near the median trade size for him over the last several quarters [3] Growth Catalysts - GeneDx has strong growth prospects, particularly following its acquisition of Fabric Genomics, which enhances its AI-driven test interpretations and expands its genomics testing portfolio [12] - The company is targeting a larger patient population by expanding testing to outpatient pediatrics, NICU patients, and newborns [11] - Management has raised its full-year revenue guidance to a range of $360 million to $375 million, up from the previous forecast of $350 million to $360 million [10]

Core Viewpoint - GeneDx Holdings Corp. is anticipated to report a year-over-year increase in earnings driven by higher revenues, with a consensus outlook suggesting a significant earnings surprise could impact its stock price in the near term [1][2]. Company Summary - The upcoming earnings report is expected to show quarterly earnings of $0.10 per share, reflecting a year-over-year increase of +190.9%. Revenues are projected to reach $84.7 million, which is a 20.1% increase from the same quarter last year [3]. - The consensus EPS estimate has been revised down by 7.81% over the last 30 days, indicating a reassessment by analysts regarding the company's earnings prospects [4]. - The Most Accurate Estimate for GeneDx Holdings is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +5.26%. The company currently holds a Zacks Rank of 2, suggesting a strong likelihood of beating the consensus EPS estimate [12]. Earnings Surprise History - In the last reported quarter, GeneDx Holdings was expected to post earnings of $0.11 per share but actually delivered earnings of $0.28, resulting in a surprise of +154.55%. The company has beaten consensus EPS estimates in each of the last four quarters [13][14]. Industry Context - In the Zacks Medical Services industry, Revvity is expected to report earnings of $1.14 per share for the quarter ended June 2025, indicating a year-over-year decline of -6.6%. Revenue for Revvity is expected to be $711.27 million, up 2.8% from the previous year [18]. - Revvity's consensus EPS estimate has remained unchanged over the last 30 days, but a higher Most Accurate Estimate has led to an Earnings ESP of +0.88%. This suggests Revvity is also likely to beat the consensus EPS estimate, having done so in each of the trailing four quarters [19].

Core Viewpoint - DJS Law Group is investigating GeneDx Holdings Corp. for potential violations of securities laws, focusing on allegations of fraudulent activities and misleading statements made by the company [1][2]. Group 1: Investigation Details - The investigation is centered on whether GeneDx made false or misleading statements or failed to disclose material information relevant to investors [2]. - A report by Grizzly Research claims that GeneDx's growth is largely an illusion, driven by fraudulent schemes aimed at manipulating Medicaid and Medicare programs to artificially inflate revenue [2]. - Allegations include that GeneDx inflated earnings through the unlawful practice of "code stacking," which allows billing for services that do not meet appropriate standards [2]. Group 2: Insider Trading Allegations - The report also alleges that CEO Katherine Stueland and CFO Kevin Feeley have routinely sold their shares upon vesting without participating in open market acquisitions, suggesting insider awareness of potential threats to the business [2]. Group 3: DJS Law Group's Focus - DJS Law Group aims to enhance investor returns through balanced counseling and aggressive advocacy, specializing in securities class actions and corporate governance litigation [2].